GLP-1 medications, such as Ozempic and Wegovy, are injected into the fatty layer beneath the skin to manage blood sugar and aid in weight management. The recommended injection sites include the ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this ...

Common GLP-1s include semaglutides like Ozempic and Wegovy, and tirzepatides like Zepbound and Mounjaro. These drugs work by mimicking a natural hormone to regulate appetite, blood sugar, and feelings ...

While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...

Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% ...

The discovery of GLP-1 and its role in regulating blood glucose was a major scientific breakthrough in diabetes research, yet turning this peptide hormone into an effective medication was no easy task ...

Injectable GLP-1s have shown slightly higher effectiveness for weight loss in clinical trials compared to oral versions. Both forms share similar gastrointestinal side effects, such as nausea and ...

Experts describe the development of oral GLP-1 medication as a “pivotal” improvement in the accessibility and adherence to obesity drugs. As of February 2026, only Wegovy and Rybelsus are available in ...

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a ...